Digging Up the Details on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

On 04 Feb 2020, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) spotted trading -27.44% off 52-week high price. On the other end, the stock has been noted 8.83% away from the low price over the last 52-weeks. The stock changed 2.07% to recent value of $102.94. The stock transacted 1820238 shares during most recent day however it has an average volume of 1784.42K shares.

Alexion Pharmaceuticals, Inc. (ALXN) recently reported financial results for the fourth quarter and full year of 2019. Total revenues for the full year of 2019 were $4,991.1M, a 21 percent increase contrast to 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $45.1M, inclusive of hedging activities. On a GAAP basis, diluted EPS for the full year of 2019 was $10.70, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, contrast to $0.35 in the previous year, inclusive of $1,183.0M of expense related to the value of the in-process research and development assets purchased in 2018. Non-GAAP diluted EPS for the full year of 2019 was $10.53, a 33 percent increase versus the previous year.

Total revenues in the fourth quarter were $1,384.3M, a 23 percent increase contrast to the same period in 2018. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $13.1M, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $4.00, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, contrast to $(0.20) in the previous year, inclusive of $379.3M of expense related to the value of the in-process research and development asset purchased in connection with our acquisition of Syntimmune in the fourth quarter of 2018. Non-GAAP diluted EPS for the fourth quarter of 2019 was $2.71, a 27 percent increase versus the fourth quarter of 2018.

Full Year 2019 Financial Highlights

Net product sales were $4,990.0M, contrast to $4,130.1M in 2018.

SOLIRIS® (eculizumab) net product sales were $3,946.4M, contrast to $3,563.0M in 2018, representing an 11 percent increase.

ULTOMIRIS® (ravulizumab-cwvz) net product sales were $338.9M in 2019.

STRENSIQ® (asfotase alfa) net product sales were $592.5M, contrast to $475.1M in 2018, representing a 25 percent increase.

KANUMA® (sebelipase alfa) net product sales were $112.2M, contrast to $92.0M in 2018, representing a 22 percent increase.

GAAP cost of sales was $394.5M, contrast to $374.3M in 2018. Non-GAAP cost of sales was $380.3M, contrast to $352.5M in 2018.

GAAP R&D expense was $886.0M, contrast to $730.4M in 2018. Non-GAAP R&D expense was $720.9M, contrast to $646.2M in 2018.

GAAP SG&A expense was $1,261.1M, contrast to $1,111.8M in 2018. Non-GAAP SG&A expense was $1,099.9M, contrast to $953.3M in 2018.

GAAP income tax benefit was $225.5M, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, contrast to expense of $164.6M in 2018. Non-GAAP income tax expense was $359.4M, contrast to $310.0M in 2018.

GAAP diluted EPS was $10.70, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property, contrast to $0.35 in 2018, inclusive of $1,183.0M of expense related to the value of the in-process research and development assets purchased in 2018. Non-GAAP diluted EPS was $10.53, contrast to $7.92 in 2018.

Fourth Quarter 2019 Financial Highlights

Net product sales were $1,384.2M in the fourth quarter of 2019, contrast to $1,128.5M in the fourth quarter of 2018.

SOLIRIS net product sales were $1,013.1M, contrast to $976.7M in the fourth quarter of 2018, representing a 4 percent increase.

ULTOMIRIS net product sales were $170.2M in the fourth quarter of 2019.

STRENSIQ net product sales were $166.8M, contrast to $126.1M in the fourth quarter of 2018, representing a 32 percent increase.

KANUMA net product sales were $34.1M, contrast to $25.7M in the fourth quarter of 2018, representing a 33 percent increase.

GAAP cost of sales was $114.3M, contrast to $96.8M in the fourth quarter of 2018. Non-GAAP cost of sales was $110.8M, contrast to $93.0M in the fourth quarter of 2018.

GAAP R&D expense was $269.6M, contrast to $205.6M in the fourth quarter of 2018. Non-GAAP R&D expense was $226.7M, contrast to $164.0M in the fourth quarter of 2018.

GAAP SG&A expense was $381.0M, contrast to $318.7M in the fourth quarter of 2018. Non-GAAP SG&A expense was $340.0M, contrast to $278.0M in the fourth quarter of 2018.

GAAP income tax benefit was $287.0M, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property in the fourth quarter of 2019, contrast to expense of $12.1M in the fourth quarter of 2018. Non-GAAP income tax expense was $85.8M, contrast to $88.5M in the fourth quarter of 2018.

GAAP diluted EPS was $4.00, inclusive of one-time tax benefits related to intra-entity asset transfers of intellectual property in the fourth quarter of 2019, contrast to $(0.20) in the fourth quarter of 2018, inclusive of $379.3M of expense related to the value of the in-process research and development asset purchased in connection with our acquisition of Syntimmune. Non-GAAP diluted EPS was $2.71, contrast to $2.14 in the fourth quarter of 2018.

Its earnings per share (EPS) expected to touch remained -95.70% for this year while earning per share for the next 5-years is expected to reach at 14.38%. ALXN has a gross margin of 92.00% and an operating margin of 30.70% while its profit margin remained 28.20% for the last 12 months.   According to the most recent quarter its current ratio was 4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -4.92% from the mean of 20 days, -6.25% from mean of 50 days SMA and performed -9.58% from mean of 200 days price. Company’s performance for the week was -3.77%, -3.26% for month and YTD performance remained -4.82%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *